With the two days' decline, it has slipped 17 per cent from its 52-week high level of Rs 5,614, touched on July 7, 2021.
Dr Reddy’s reported a weak result on the margins front while revenues were in-line with analyst estimates supported by strong growth in domestic formulations (DF). Profitability, meanwhile, was impacted due to below par margins.
The company has reported a consolidated net profit of Rs 570.8 crore in Q1FY22, a 1.5 per cent dip on a year-on-year basis (YoY), while revenue from operations grew by 11.4 per cent to Rs 4,919.4 crore during the quarter.
Ebitda (earnings before interest, taxes, depreciation, and amortization) margins were down 560 basis points (bps) YoY and 310 bps sequentially at 20.7 per cent during the quarter. Gross profit margin decreased by 380 bps over the previous year and 150 bps sequentially, majorly on account of price erosion and increase in inventory provisions related to few products.
The management remains committed to working on cost rationalisation, especially on the SGN&A front and calibrating of R&D spend more towards Global Generics front & biosimilars and lower towards proprietary products. Key growth drivers in the near term would be key launches across geographies besides continuing growth momentum in Global Generics, especially in India and Russia, ICICI Securities said in a note.
However, in a separate development, Dr Reddy’s said it had received a subpoena (written order to attend court to give evidence) from the American market regulator Securities and Exchange Commission (SEC) for producing documents concerning the Commonwealth of Independent States (CIS) geographies.
“We await clarity on the further course of action post the receipt of a subpoena from the Securities and Exchange Commission (SEC) for the production of documents for allegations related to improper payments to healthcare professionals in Ukraine and certain other geographies. We believe the current valuation adequately factors in the upside in the base business and incremental contribution from niche launches. Hence, we remain Neutral,” Motilal Oswal Financial Services said said in a result update.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in